The Genome sequence of the SARS-associated coronavirus.

Marra, Marco A; Jones, Steven J M; Astell, Caroline R; Holt, Robert A; Brooks-Wilson, Angela; Butterfield, Yaron S N; Khattra, Jaswinder; Asano, Jennifer K; Barber, Sarah A; Chan, Susanna Y; Cloutier, Alison; Coughlin, Shaun M; Freeman, Doug; Girn, Noreen; Griffith, Obi L; Leach, Stephen R; Mayo, Michael; McDonald, Helen; Montgomery, Stephen B; Pandoh, Pawan K; Petrescu, Anca S; Robertson, A Gordon; Schein, Jacqueline E; Siddiqui, Asim; Smailus, Duane E; Stott, Jeff M; Yang, George S; Plummer, Francis; Andonov, Anton; Artsob, Harvey; Bastien, Nathalie; Bernard, Kathy; Booth, Timothy F; Bowness, Donnie; Czub, Martin; Drebot, Michael; Fernando, Lisa; Flick, Ramon; Garbutt, Michael; Gray, Michael; Grolla, Allen; Jones, Steven; Feldmann, Heinz; Meyers, Adrienne; Kabani, Amin; Li, Yan; Normand, Susan; Stroher, Ute; Tipples, Graham A; Tyler, Shaun; Vogrig, Robert; Ward, Diane; Watson, Brynn; Brunham, Robert C; Krajden, Mel; Petric, Martin; Skowronski, Danuta M; Upton, Chris; Roper, Rachel L

We sequenced the 29,751-base genome of the severe acute respiratory syndrome (SARS)-associated coronavirus known as the Tor2 isolate. The genome sequence reveals that this coronavirus is only moderately related to other known coronaviruses, including two human coronaviruses, HCoV-OC43 and HCoV-229E. Phylogenetic analysis of the predicted viral proteins indicates that the virus does not closely resemble any of the three previously known groups of coronaviruses. The genome sequence will aid in the diagnosis of SARS virus infection in humans and potential animal hosts (using polymerase chain reaction and immunological tests), in the development of antivirals (including neutralizing antibodies), and in the identification of putative epitopes for vaccine development.